In yesterday’s Wall Street session, Elevation Oncology Inc. (NASDAQ:ELEV) shares traded at $0.92, down -20.00% from the previous session.
As of this writing, 4 analysts cover Elevation Oncology Inc. (NASDAQ:ELEV). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $4.00 and a low of $1.00, we find $2.50. Given the previous closing price of $1.15, this indicates a potential upside of 117.39 percent. ELEV stock price is now -5.02% away from the 50-day moving average and -39.89% away from the 200-day moving average. The market capitalization of the company currently stands at $21.34M.
There are 1 analysts who have given it a hold rating, whereas 2 have given it a buy rating. Brokers who have rated the stock have averaged $2.50 as their price target over the next twelve months.
With the price target of $12, H.C. Wainwright recently initiated with Buy rating for Elevation Oncology Inc. (NASDAQ: ELEV).
In other news, venBio Global Strategic Fund I, 10% Owner sold 702,737 shares of the company’s stock on May 25. The stock was sold for $2,897,806 at an average price of $4.12. Upon completion of the transaction, the 10% Owner now directly owns 1,905,430 shares in the company, valued at $1.75 million. Insiders disposed of 762,931 shares of company stock worth roughly $0.7 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ELEV stock. A new stake in Elevation Oncology Inc. shares was purchased by ANNANDALE CAPITAL, LLC during the first quarter worth $28,000. In total, there are 35 active investors with 73.00% ownership of the company’s stock.
Tuesday morning saw Elevation Oncology Inc. (NASDAQ: ELEV) opened at $1.0842. During the past 12 months, Elevation Oncology Inc. has had a low of $0.72 and a high of $5.92. As of last week, the company has a debt-to-equity ratio of 0.44, a current ratio of 7.30, and a quick ratio of 7.30. The fifty day moving average price for ELEV is $0.9686 and a two-hundred day moving average price translates $1.5304 for the stock.
The latest earnings results from Elevation Oncology Inc. (NASDAQ: ELEV) was released for Jun, 2022.
Elevation Oncology Inc.(ELEV) Company Profile
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company’s lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.